I maintain a 70% allocation to SPY and 30% to EFA, as both are in bullish uptrends above their 10-month EMAs. Learn more ...
Myriad Genetics (MYGN) jumps on an earnings beat, raising 2026 revenue targets to $860M-$880M and highlighting oncology test growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results